• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Adapted Live SARS-CoV-2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5.

Adapted Live SARS-CoV-2 Vaccine Elicits Rapid Mucosal Immunity, Protects From Disease, and Reduces Shedding of XBB.1.5.

Details
Files
DOI
10.48620/97512
Publisher DOI
10.1002/eji.70196
PubMed ID
42083322
Abstract
The emergence of SARS-CoV-2 variants, like XBB.1.5, causing immune evasion and frequent breakthrough infections, emphasizes the need for vaccines that limit transmission and target newly emerging variants. Mucosal vaccines, particularly live attenuated vaccines (LAV), are promising candidates for inducing strong mucosal immune responses to prevent viral replication and transmission. Vaccination with the previously described "one-to-stop" codon-modified LAV OTS-228, carrying the ancestral spike protein, induced sterilizing immunity against ancestral SARS-CoV-2 but also broad protection against Omicron variants, including XBB.1.5, but transmission of XBB.1.5 to contacts could not be prevented completely. As a proof-of-concept, we updated OTS-228 by replacing the sequence coding for the ancestral SARS-CoV-2 spike protein with that of the XBB.1.5 variant. We applied flow cytometry to detect SARS-CoV-2-specific T cell responses, as well as ELISA and qPCR, to characterize systemic and mucosal immune responses in Syrian hamsters in detail. The new OTS construct designated as "OTS-300" exhibited an optimal safety profile in Syrian hamsters comparable to the original candidate vaccine. A single-dose intranasal (i.n.) vaccination with OTS-300 protects against disease, substantially limits XBB.1.5 replication, and reduces transmission in Syrian hamsters, showcasing the adaptability of the OTS platform for other emerging variants. OTS-300 induced accelerated mucosal and systemic antibody responses and reduced virus-mediated inflammation as compared with an intramuscularly delivered mRNA vaccine encoding the XBB.1.5 Spike.
Date Issued
2026-05
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
500 Science > 590 Animals (Zoology)
600 Technology > 630 Agriculture
Language(s)
en
Author(s)
Kochmann, Jana
Britzke, Tobias
Halwe, Nico Joël
Ulrich, Lorenz
Breithaupt, Angele
Barut, G. Tuba  
Institute of Virology and Immunology  
Department of Infectious Diseases and Pathobiology (DIP)  
Ebert, Nadine  
Department of Infectious Diseases and Pathobiology (DIP)  
Trüeb, Bettina Salome  
Institute of Veterinary Bacteriology (IVB)  
Department of Infectious Diseases and Pathobiology (DIP)  
Thiel, Volker  
Department of Infectious Diseases and Pathobiology (DIP)  
Institute of Virology and Immunology  
Multidisciplinary Center for Infectious Diseases (MCID)  
Dorhoi, Anca
Beer, Martin
Hoffmann, Donata
Corleis, Björn
Schön, Jacob
Additional Credits
Multidisciplinary Center for Infectious Diseases (MCID)  
Department of Infectious Diseases and Pathobiology (DIP)  
Institute of Virology and Immunology  
Institute of Veterinary Bacteriology (IVB)  
Journal
European Journal of Immunology
Publisher
Wiley
ISSN
1521-4141
0014-2980
Access(Rights)
open.access
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify